Alcohol withdrawal Flashcards
- Alcohol withdrawal mechanism
- chronic alcohol consumption enhances GABA mediated inhibition in the CNS (similar to benzodiazepines) and inhibits NMDA-type glutamate receptors
- alcohol withdrawal is thought to be lead to the opposite (decreased inhibitory GABA and increased NMDA glutamate transmission)
Alcohol withdrawal symptoms
- symptoms start at 6-12 hours: tremor, sweating, tachycardia, anxiety
- peak incidence of seizures at 36 hours
- peak incidence of delirium tremens is at 48-72 hours: coarse tremor, confusion, delusions, auditory and visual hallucinations, fever, tachycardia
- Peak incidence of seizures in hours for alcohol withdrawal
36 hours
Peak incidence of delirium tremens in hours for alcohol withdrawal
48-72 hours: coarse tremor, confusion, delusions, auditory and visual hallucinations, fever, tachycardia
Start of symptoms in hours for alcohol withdrawal
6-12 hours
tremor, sweating, tachycardia, anxiety
Alcohol withdrawal management
- patients with a history of complex withdrawals from alcohol (i.e. delirium tremens, seizures, blackouts) should be admitted to hospital for monitoring until withdrawals stabilised
- first-line: long-acting benzodiazepines e.g. chlordiazepoxide or diazepam. Lorazepam may be preferable in patients with hepatic failure. Typically given as part of a reducing dose protocol
- carbamazepine also effective in treatment of alcohol withdrawal
- phenytoin is said not to be as effective in the treatment of alcohol withdrawal seizures
- Ensure adequate hydration with fluids
- Provide Anti-emetics to manage nausea
- Pabrinex to replenish vitamins
- Refer the patient to local drug and alcohol liaison teams for further support and management
When patients present with seizures, sometimes they remain in hospital for inpatient detoxification. This is however rare and the evidence shows that community detoxification is more effective.
scale that can be used to assess alcohol withdrawal severity
The revised Clinical Institute Withdrawal Assessment for Alcohol (CIWA) scale can be used to assess alcohol withdrawal severity
which medication is used as a DETERRANT to prevent alcohol relapse
Disulfiram (also known as Antabuse) is an irreversible inhibitor of acetaldehyde dehydrogenase. This inhibition causes the buildup of acetaldehyde.
The build-up of acetaldehyde within twenty to thirty minutes of alcohol consumption results in unpleasant symptoms, including facial flushing and nausea and vomiting. The reaction can be life-threatening, so disulfiram is not recommended for patients with underlying frailty, neurological, cardiac or hepatic conditions.
Disulfiram is taken once daily and its effects last seven days, working as a deterrent to prevent alcohol relapse
which medication can be prescribed as “anti craving” for preventing alcohol relapse
Acamprosate (or Campral) is taken three times a day and has shown to be effective in preventing alcohol relapse in combination with psychological support following detoxification in alcohol dependence syndrome.
It is typically described as an ‘anti-craving’ medication and the underlying mechanism of action remains unclear.
Acamprosate has a minimal side-effect and risk profile and is safe in combination with alcohol.
Korsakoff’s syndrome features and cause
Overview
marked memory disorder often seen in alcoholics
thiamine deficiency causes damage and haemorrhage to the mammillary bodies of the hypothalamus and the medial thalamus
in often follows on from untreated Wernicke’s encephalopathy
Features
anterograde amnesia: inability to acquire new memories
retrograde amnesia
confabulation
why is pabrinex prescribed?
Pabrinex (1 pair of ampoules once daily) to prevent Wernicke’s encephalopathy. In the presence of Wernicke’s encephalopathy symptoms, two pairs of ampoules TDS should be prescribed.
what is prescribed for patients with alcohol withdrawal seizures?
Rapid-acting benzodiazepines (such as intravenous lorazepam) for patients with alcohol-withdrawal seizures.
first line treatment for delirium tremens
Oral lorazepam as the first-line treatment for delirium tremens, with parenteral lorazepam/diazepam offered if oral treatment is declined or symptoms persist.
indications for inpatient withdrawal treatment
- Patients drinking >30 units per day
- Scoring over 30 on the SADQ score
- High risk of alcohol withdrawal seizures (previous alcohol withdrawal seizures or delirium tremens, or history of epilepsy)
- Concurrent withdrawal from benzodiazepines
- Significant medical or psychiatric comorbidity
- Vulnerable patients
- Patients under 18
investigations in alcohol withdrawal
- AUDIT and SADQ questionnaires to assess the severity of alcohol misuse.
- Blood tests to assess liver function and electrolyte balance.
- Neuroimaging may be considered in cases of persistent confusion or seizures.